H.C. Wainwright analyst Yi Chen raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $22 and keeps a Buy rating on the shares. The company reported a beat in Q3 and raised its 2024 revenue guidance, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Sees Strong Growth in Q3 2024
- Bausch + Lomb reports Q3 adjusted EPS 17c, consensus 22c
- Bausch + Lomb raises FY24 revenue view to $4.73B-$4.83B from $4.7B-$4.8B
- Bausch Health price target raised to $10 from $8.50 at RBC Capital
- Bausch + Lomb price target raised to $23 from $20 at RBC Capital